The Changing Pathology of Lung Cancer

Surgical Oncology Clinics of North America

Volumn 20, Issue 4, 2011, Pages 637-653

  Fan, Zhen ^a   Schraeder, Richard ^b  

^a Department of Pathology   (United States)

^b St Joseph's Medical Center   (United States)

Author keywords

Cancer; Classification; Lung; Pathology; Therapy

Indexed keywords

BCR ABL PROTEIN; BEVACIZUMAB; CD56 ANTIGEN; CHROMOGRANIN; CISPLATIN; CRIZOTINIB; CYTOKERATIN 20; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; K RAS PROTEIN; PEMETREXED; PLATINUM DERIVATIVE; PROTEIN P63; SYNAPTOPHYSIN; THYROID TRANSCRIPTION FACTOR 1; TRANSCRIPTION FACTOR CDX2;

ATYPICAL LUNG CARCINOID; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOMA; LUNG LARGE CELL CARCINOMA; LUNG LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TUMOR; REVIEW; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TYPICAL LUNG CARCINOID;

HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING;

EID: 80053926252     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2011.07.004     Document Type: Review

References (86)

1. Rossi A., Maione P., Bareschino M.A., et al. The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making. Curr Med Chem 2010, 17(11):1030-1038.
2. Molina J.R., Yang P., Cassivi S.D., et al. Non-small cell lung cancer; epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83(5):584-594.
3. Cagle P.T., Allen T.C., Dacic S., et al. Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med 2011, 135:110-116.
4. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
5. Sandler A., Gray R., Perry M.C. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
6. Travis W.D., Brambilla E., Muller-Hermelink H.K., et al. In: World Health Organization classification of tumours 2004, vol. 10. Pathology and genetics of tumours of the lung, pleura, thymus and heart, IARC Press, Lyon (France), p.12-77.
7. Funai K., Yokose T., Ishii G., et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol 2003, 27:978-984.
8. Lantuejoul S., Salameire D., Salon C., et al. Pulmonary preneoplasia-sequential molecular carcinogenetic events. Histopathology 2009, 54(1):43-54.
9. Watanabe Y., Yokose T., Sakuma Y., et al. Alveolar space filling ratio as a favorable prognostic factor in small peripheral squamous cell carcinoma of the lung. Lung Cancer 2011, 73(2):217-221.
10. Chansky K., Sculier J.P., Crowley J.J., et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009, 4(7):792-801.
11. Parkin D.M., Whelan S.L., Ferlay J., et al. IARC Scientific Publications No. 155 2002, vol. 8. Cancer incidence in five continents, IARCPress, Lyon (France).
12. Colby T.V., Koss M., Travis W.D. Tumors of the lower respiratory tract 1995, Armed Forces Institute of Pathology, Washington. 3rd edition.
13. Wahbah M., Boroumand N., Castro C., et al. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol 2007, 11(2):89-96.
14. Travis W.D., Travis L.B., Devesa S.S. Lung cancer. Cancer 1995, 75(Suppl 1):191-202.
15. Charloux A., Quoix E., Wolkove N., et al. The increasing incidence of lung adenocarcinoma: reality or artifact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 1997, 26(1):14-23.
16. Teraski H., Niki T., Matsuno Y., et al. Lung adenocarcinoma with mixed bronchiolo-alveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol 2003, 27:937-951.
17. Maeda R., Isowa N., Onuma H., et al. Lung adenocarcinomas with micropapillary components. Gen Thorac Cardiovasc Surg 2009, 57(10):534-539.
18. Kamiya K., Hayashi Y., Douguchi J., et al. Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma. Mod Pathol 2008, 21(8):992-1001.
19. Sanchez-Mora N., Presmanes M.C., Monroy V., et al. Micropapillary lung adenocarcinoma: a distinctive histologic subtype with prognostic significance. Case series. Hum Pathol 2008, 39(3):324-330.
20. Tsutsumida H., Nomoto M., Goto M., et al. A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Mod Pathol 2007, 20(6):638-647.
21. Miyoshi T., Satoh Y., Okumura S., et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 2003, 27(1):101-109.
22. Travis W.D., Brambilla E., Noguchi M., et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6(2):244-285.
23. Motoi N., Szoke J., Riely G., et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 2008, 32(6):810-824.
24. Raz D.J., He B., Rosell R., et al. Bronchioloalveolar carcinoma: a review. Clin Lung Cancer 2006, 7(5):313-322.
25. Garfield D.H., Cadranel J., West H.L. Bronchioloalveolar carcinoma: the case for two diseases. Clin Lung Cancer 2008, 9(1):24-29.
26. Manning J.T., Spjut H.J., Tschen J.A. Bronchioloalveolar carcinoma: the significance of two histopathologic types. Cancer 1984, 54:525-534.
27. Ebright M.I., Zakowski M.F., Martin J., et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002, 74:1640-1647.
28. Travis W.D., Garg K., Franklin W.A., et al. Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol 2006, 1(Suppl 9):S13-S19.
29. Sakuri H., Dobashi Y., Mizutani E., et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. Ann Thorac Surg 2004, 78(5):1728-1733.
30. Morandi L., Asioli S., Cavazza A., et al. Genetic relationship among atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, and adenocarcinoma of the lung. Lung Cancer 2007, 56:35-42.
31. Koga T., Hashimoto S., Sugio K., et al. Lung adenocarcinoma with bronchioloalveolar component is frequently associated with foci of high-grade atypical adenomatous hyperplasia. Am J Clin Pathol 2002, 117:464-470.
32. Chapman A.D., Kerr K.M. The association between atypical adenomatous hyperplasia and primary lung cancer. Br J Cancer 2000, 83:632-636.
33. Mori M., Rao S.K., Popper H.H., et al. Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod Pathol 2001, 14(2):72-84.
34. Moro D., Brichon P.Y., Brambilla E., et al. Basaloid bronchial carcinoma. A histologic group with a poor prognosis. Cancer 1994, 73:2734-2739.
35. Tamboli P., Toprani T.H., Amin M.B., et al. Carcinoma of lung with rhabdoid features. Hum Pathol 2004, 35(1):8-13.
36. Han A.J., Xiong M., Gu Y.Y., et al. Lymphoepithelioma-like carcinoma of the lung with a better prognosis: a clinicopathologic study of 32 cases. Am J Clin Pathol 2001, 115:841-850.
37. Chan J.K., Hui P.K., Tsang W.Y., et al. Primary lymphoepithelioma-like carcinoma of the lung. A clinicopathologic study of 11 cases. Cancer 1995, 76:413-422.
38. Castro C.Y., Ostrowski M.L., Barrios R., et al. Relationship between Epstein-Barr virus and lymphoepithelioma-like carcinoma of the lung: a clinicopathologic study of 6 cases and review of the literature. Hum Pathol 2001, 32(8):863-872.
39. Nakagawa K., Yasumitsu T., Fukuhara K., et al. Poor prognosis after lung resection for patients with adenosquamous carcinoma of the lung. Ann Thorac Surg 2003, 75:1740-1744.
40. Hsia J.Y., Chen C.Y., Hsu C.P., et al. Adenosquamous carcinoma of the lung. Surgical results compared with squamous cell and adenocarcinoma. Scand Cardiovasc J 1999, 33:29-32.
41. Ben Y., Yu H., Wang Z., et al. Adenosquamous lung carcinoma: clinical characteristics, surgical treatment and prognosis. Chin Med Sci J 2000, 15(4):238-240.
42. Naunheim K.S., Taylor J.R., Skosey C., et al. Adenosquamous lung carcinoma: clinical characteristics, treatment, and prognosis. Ann Thorac Surg 1987, 44:462-466.
43. Fitzgibbons P.L., Kern W.H. Adenosquamous carcinoma of the lung: a clinical and pathologic study of seven cases. Hum Pathol 1985, 16:463-466.
44. Hofmann H.S., Knolle J., Neef H. The adenosquamous lung carcinoma: clinical and pathological characteristics. J Cardiovasc Surg 1994, 35:543-547.
45. Nakajima M., Kasai T., Hashimoto H., et al. Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases. Cancer 1999, 86(4):608-616.
46. Ro J.Y., Chen J.L., Lee J.S., et al. Sarcomatoid carcinoma of the lung. Immunohistochemical and ultrastructural studies of 14 cases. Cancer 1992, 69(2):376-386.
47. Gustafsson B.I., Kidd M., Chan A., et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008, 113(1):5-21.
48. Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 2010, 134:1628-1638.
49. Takei H., Asamura H., Maeshima A., et al. Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 2002, 124:285-292.
50. McCaughan B.C., Martini N., Bains M.S. Bronchial carcinoids: review of 124 cases. J Thorac Cardiovasc Surg 1985, 89(1):8-17.
51. Fink G., Krelbaum T., Yellin A., et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 2001, 119(6):1647-1651.
52. Sachithanandan N., Harle R.A., Burgess J.R. Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer 2005, 103(3):509-515.
53. Debelenko L.V., Swalwell J.I., Kelley M.J., et al. MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. Genes Chromosomes Cancer 2000, 28:58-65.
54. Vallieres E., Shepherd F.A., Crowley J., et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009, 4(9):1049-1059.
55. Shepherd F.A., Crowley J., Van Houtte P., et al. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007, 2(12):1067-1077.
56. Travis W.D., Giroux D.J., Chansky K., et al. The IASLC lung cancer staging project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2008, 3(11):1213-1223.
57. Travis W.D., Rush W., Flieder D.B., et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria of atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1988, 22(8):934-944.
58. Mezzetti M., Raveglia F., Panigalli T., et al. Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification. Ann Thorac Surg 2003, 76(6):1838-1842.
59. Morandi U., Casali C., Rossi G. Bronchial typical carcinoid tumors. Semin Thorac Cardiovasc Surg 2006, 18(3):191-198.
60. Thomas C.F., Tazelaar H.D., Jett J.R. Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph node involvement. Chest 2001, 119(4):1143-1150.
61. Miller R.R., Muller N.L. Neuroendocrine cell hyperplasia and obliterative bronchiolitis in patients with peripheral carcinoid tumors. Am J Surg Pathol 1995, 19(6):653-658.
62. Travis WD., Colby TV., Corrin B., et al. WHO Histological Classification of tumours. Histological typing of lung and pleural tumours 1999, Springer-Verlag, Berlin (Germany). 3rd edition.
63. Rizvi S.M., Goodwill J., Lim E., et al. The frequency of neuroendocrine cell hyperplasia in patients with pulmonary neuroendocrine tumours and non-neuroendocrine cell carcinomas. Histopathology 2009, 55(3):332-337.
64. Beasley M.B., Thunnissen F.B., Brambilla E., et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 2000, 31(10):1255-1265.
65. Wick M.R., Leslie K.O., Ritter J.H., et al. Neuroendocrine neoplasms of the lung. Practical pulmonary pathology: a diagnostic approach 2005, 424-448. Elsevier, Churchill Livingstone (Philadelphia).
66. Lim E., Belcher E., Yap Y.K., et al. The role of surgery in the treatment of limited disease small cell lung cancer: time to reevaluate. J Thorac Oncol 2008, 3(11):1267-1271.
67. Nicholson S.A., Beasley M.B., Brambilla E., et al. Small cell lung carcinoma (SCLS): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002, 26:1184-1197.
68. Sehested M., Hirsch F.R., Osterlind K., et al. Morphologic variations of small cell lung cancer. A histopathologic study of pretreatment and posttreatment specimens in 104 patients. Cancer 1986, 57(4):804-807.
69. Radice P.A., Matthews M.J., Ihde D.C., et al. The clinical behavior of "mixed" small cell/large cell bronchogenic carcinoma compared to "pure" small cell subtypes. Cancer 1982, 50(12):2894-2902.
70. den Bakker M.A., Willemsen S., Grünberg K., et al. Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability. Histopathology 2010, 56(3):356-363.
71. Travis W.D., Gal A.A., Colby T.V., et al. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 1998, 29(3):272-279.
72. Zamecnik J., Kodet R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Virchows Arch 2002, 400:353-361.
73. Lau S.K., Desrochers M.J., Luthringer D.J. Expression on thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol 2002, 15:538-542.
74. Shah R.N., Badve S., Papreddy K., et al. Expression of cytokeratin 20 in mucinous bronchioalveolar carcinoma. Hum Pathol 2002, 33(9):915-920.
75. Kaufmann O., Georgi T., Dietel M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol 1997, 28(12):1373-1378.
76. Kaufmann O., Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology 2000, 36:415-420.
77. Folpe A.L., Gown A.M., Lamps L.W., et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 1999, 12:5-8.
78. Lin X., Saad R.S., Luckasevic T.M., et al. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol 2007, 15(4):407-414.
79. Srivastava A., Hornick J.L. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg Pathol 2009, 33(4):626-632.
80. Guinee D.B., Fishback N.F., Koss M.N., et al. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol 1994, 102(4):406-414.
81. Aslan D.L., Gulbahce H.E., Pambuccian S.E., et al. Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact. Am J Clin Pathol 2005, 123(6):874-878.
82. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med 2005, 353(2):133-144.
83. Maemondo M., Inove A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
84. Cataldo V.D., Gibbons D.L., Perez-Soler R., et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011, 364(10):947-955.
85. Kwak E.L., Banq Y.J., Camidge D.R., et al. Anaplastic Lymphoma Kinase Inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1603-1703.
86. Olaussen K.A., Dunant A., Fouret P., et al. DNA Repair by ERCC1 in Non-small-cell lung cancer and cisplatin-based adjuvant therapy. N Engl J Med 2006, 355(10):983-991.